Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: ....

Ward: ....

PATIENT:

Name: ....

NHI: ....

Febuxostat

INITIATION – Gout

Prerequisites (tick boxes where appropriate)

○ Patient has been diagnosed with gout

and

○ The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose

or

○ The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose

or

○ The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note)

or

○ The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout.

INITIATION – Tumour lysis syndrome
Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

○ Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

○ Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome

and

○ Patient has a documented history of allopurinol intolerance

---

CONTINUATION – Tumour lysis syndrome
Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

○ Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

○ The treatment remains appropriate and patient is benefitting from treatment

---

I confirm that the above details are correct:

Signed: .... Date: ....